Renal Cell Carcinoma (First-Line Advanced/Metastatic) | Decision Base | US | 2015
What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers?
Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the treatment of advanced/metastatic renal cell carcinoma (RCC) in the first line. While mTOR inhibitors such as temsirolimus (Pfizer’s Torisel) have expanded the treatment options for patients in this setting, especially those with poor-prognosis disease, RCC remains incurable, and most first-line patients relapse following treatment. Significant clinical and commercial opportunities remain for new therapies that can provide greater survival benefits than the currently available agents.
Related Market Assessment Reports
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
